Martin Scobie

Martin Scobie

Auto-generated profile, based on publicly available information

Martin Scobie

Karolinska Institutet

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2014 in Nature
Verified
Journal Article
Closed access
HGHelge Gad
Helge Gad
TKTobias Koolmeister
Tobias Koolmeister
AJAnn-Sofie Jemth
Ann-Sofie Jemth
SESaeed Eshtad
Saeed Eshtad
SJSylvain A Jacques
Sylvain A Jacques
THThomas Helleday
Thomas Helleday

16 November 2018 in Science
Verified
Journal Article
Closed access
PDF file
TTorkild Visnes
Torkild Visnes
ACArmando Cázares-Körner
Armando Cázares-Körner
WHWenjing Hao
Wenjing Hao
OWOlov Wallner
Olov Wallner
GMGeoffrey Masuyer
Geoffrey Masuyer
THThomas Helleday
Thomas Helleday
DNA binding as an anti-inflammatory: Mice that lack the gene encoding 8-oxoguanine DNA glycosylase 1 (OGG1) show resistance to inflammation. This enzyme binds to sites of oxidative DNA damage and initiates DNA base excision repair. Visnes et al. developed a small-molecule drug that acts as a potent and selective active-site inhibitor that stops OGG1 from recognizing its DNA substrate (see the Perspective by Samson). The drug inhibited DNA repair and modified OGG1 chromatin dynamics, which resulted in the inhibition of proinflammatory pathway genes. The drug was well tolerated by mice and suppressed lipopolysaccharide- and tumor necrosis factor–α–mediated neutrophilic inflammation in the lungs. Science , this issue p. 834 ; see also p. 748

1 December 2016 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
UBUlrika Warpman Berglund
Ulrika Warpman Berglund
KSK. Sanjiv
K. Sanjiv
HGH. Gad
H. Gad
CKC. Kalderén
C. Kalderén
TKT. Koolmeister
T. Koolmeister
THThomas Helleday
Thomas Helleday
Background Previously, we showed cancer cells rely on the MTH1 protein to prevent incorporation of otherwise deadly oxidised nucleotides into DNA and we developed MTH1 inhibitors which selectively kill cancer cells. Recently, several new and potent inhibitors of MTH1 were demonstrated to be non-toxic to cancer cells, challenging the utility of MTH1 inhibition as a target for cancer treatment. Material and methods Human cancer cell lines were exposed in vitro to MTH1 inhibitors or depleted of MTH1 by siRNA or shRNA. 8-oxodG was measured by immunostaining and modified comet assay. Thermal Proteome profiling, proteomics, cellular thermal shift assays, kinase and CEREP panel were used for target engagement, mode of action and selectivity investigations of MTH1 inhibitors. Effect of MTH1 inhibition on tumour growth was explored in BRAF V600E-mutated malignant melanoma patient derived xenograft and human colon cancer SW480 and HCT116 xenograft models. Results Here, we demonstrate that recently described MTH1 inhibitors, which fail to kill cancer cells, also fail to introduce the toxic oxidized nucleotides into DNA. We also describe a new MTH1 inhibitor TH1579, (Karonudib), an analogue of TH588, which is a potent, selective MTH1 inhibitor with good oral availability and demonstrates excellent pharmacokinetic and anti-cancer properties in vivo. Conclusion We demonstrate that in order to kill cancer cells MTH1 inhibitors must also introduce oxidized nucleotides into DNA. Furthermore, we describe TH1579 as a best-in-class MTH1 inhibitor, which we expect to be useful in order to further validate the MTH1 inhibitor concept.

20 June 2014 in Scientific Reports
Verified
Journal Article
Open access
CGChunxia Gao
Chunxia Gao
EBEmer Bourke
Emer Bourke
MSMartin Scobie
Martin Scobie
MFMelina Arcos Famme
Melina Arcos Famme
TKTobias Koolmeister
Tobias Koolmeister
James BrownJames Brown
James Brown
Histone acetylation is required for many aspects of gene regulation, genome maintenance and metabolism and dysfunctional acetylation is implicated in numerous diseases, including cancer. Acetylation is regulated by histone acetyltransferases (HATs) and histone deacetylases and currently, few general HAT inhibitors have been described. We identified the HAT Tip60 as an excellent candidate for targeted drug development, as Tip60 is a key mediator of the DNA damage response and transcriptional co-activator. Our modeling of Tip60 indicated that the active binding pocket possesses opposite charges at each end, with the positive charges attributed to two specific side chains. We used structure based drug design to develop a novel Tip60 inhibitor, TH1834, to fit this specific pocket. We demonstrate that TH1834 significantly inhibits Tip60 activity in vitro and treating cells with TH1834 results in apoptosis and increased unrepaired DNA damage (following ionizing radiation treatment) in breast cancer but not control cell lines. Furthermore, TH1834 did not affect the activity of related HAT MOF, as indicated by H4K16Ac, demonstrating specificity. The modeling and validation of the small molecule inhibitor TH1834 represents a first step towards developing additional specific, targeted inhibitors of Tip60 that may lead to further improvements in the treatment of breast cancer.

17 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
BPBrent Page
Brent Page
NVNicholas C. K. Valerie
Nicholas C. K. Valerie
RWRoni Wright
Roni Wright
OWOlov Wallner
Olov Wallner
RIRebecka Isaksson
Rebecka Isaksson
THThomas Helleday
Thomas Helleday
With a diverse network of substrates, NUDIX hydrolases have emerged as a key family of nucleotide-metabolizing enzymes. NUDT5 (also called NUDIX5) has been implicated in ADP-ribose and 8-oxo-guanine metabolism and was recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells. Here, we further elucidate the physiological relevance of known NUDT5 substrates and underscore the biological requirement for NUDT5 in gene regulation and proliferation of breast cancer cells. We confirm the involvement of NUDT5 in ADP-ribose metabolism and dissociate a relationship to oxidized nucleotide sanitation. Furthermore, we identify potent NUDT5 inhibitors, which are optimized to promote maximal NUDT5 cellular target engagement by CETSA. Lead compound, TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. We herein present TH5427 as a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism.

24 June 2022 in Science
Verified
Journal Article
Closed access
MMMaurice Michel
Maurice Michel
CBCarlos Benítez-Buelga
Carlos Benítez-Buelga
PCPatricia A. Calvo
Patricia A. Calvo
BHBishoy M. F. Hanna
Bishoy M. F. Hanna
OMOliver Mortusewicz
Oliver Mortusewicz
THThomas Helleday
Thomas Helleday
Oxidative DNA damage is recognized by 8-oxoguanine (8-oxoG) DNA glycosylase 1 (OGG1), which excises 8-oxoG, leaving a substrate for apurinic endonuclease 1 (APE1) and initiating repair. Here, we describe a small molecule (TH10785) that interacts with the phenylalanine-319 and glycine-42 amino acids of OGG1, increases the enzyme activity 10-fold, and generates a previously undescribed β,δ-lyase enzymatic function. TH10785 controls the catalytic activity mediated by a nitrogen base within its molecular structure. In cells, TH10785 increases OGG1 recruitment to and repair of oxidative DNA damage. This alters the repair process, which no longer requires APE1 but instead is dependent on polynucleotide kinase phosphatase (PNKP1) activity. The increased repair of oxidative DNA lesions with a small molecule may have therapeutic applications in various diseases and aging.